Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

Open access

Abstract

Imatinib mesylate treatment markedly reduces the burden of leukemia cells in chronic myelogenous leukemia (CML) patients. However, patients remain at risk for relapse on discontinuing treatment. We have previously shown that residual BCR-ABL+ progenitors can be detected in CML patients within the first 2 years of imatinib treatment. However, reduced rates of relapse and continued decline of BCR-ABL levels with prolonged treatment, together with the ability of selected patients to maintain remission after discontinuing treatment, led us to investigate whether prolonged imatinib exposure resulted in reduction or elimination of BCR-ABL+ stem cells. We evaluated BCR-ABL expression in CD34+CD38+ (38+) committed progenitors and CD34+CD38− (38−) stem/primitive progenitor cells in samples from CML patients on imatinib treatment for at least 4 years with cytogenetic and molecular response. High levels of BCR-ABL expression were maintained over time in the 38− stem cell fraction. The absolute frequency of BCR-ABL+ cells as determined by limiting dilution analysis was consistently higher in 38− compared with 38+ cells. Transplantation into NOD/SCID-IL2Rγ-chain knockout mice demonstrated that BCR-ABL+ cells had long-term in vivo repopulating capacity. These results directly demonstrate that BCR-ABL+ stem cells persist in CML patients despite prolonged treatment with imatinib, and support ongoing efforts to target this population.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2010-12-327437

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 31 references

Cited by

See all 247

Metadata

Authors
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R.
Affiliations
  • Division of Hematopoietic Stem Cell and Leukemia Research,
  • City Of Hope National Medical Center (US)
  • Department of Hematology and Hematopoietic Cell Transplantation, and
Venue
Blood
Published
2011-11-17
Volume
118
Issue
20
Pages
5565-5572
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2062166095
Cited by
245
References
31
Citations by year
2026: 7 · 2025: 6 · 2024: 7 · 2023: 13 · 2022: 10 · 2021: 17 · 2020: 15 · 2019: 20 · 2018: 13 · 2017: 27 · 2016: 25 · 2015: 9 · 2014: 21 · 2013: 36 · 2012: 18
FWCI
16.68
Type
journal article
Language
en
Open access
Locations
  • Blood (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute (R01CA095684, R01 CA95684)
Topics
  • Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
Keywords
chronic myeloid leukemia, leukemia stem cells, imatinib mesylate, BCR-ABL, CD34+CD38- cells, relapse after treatment discontinuation
MeSH terms
Imatinib Mesylate, Animals, Antineoplastic Agents, Benzamides, Bone Marrow, Humans, Neoplasm Transplantation, Piperazines, Pyrimidines, Remission Induction, Substance Withdrawal Syndrome, Time Factors, Neoplastic Stem Cells, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Fusion Proteins, bcr-abl, Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Neoplasm, Residual, Xenograft Model Antitumor Assays, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. https://app.cochat.ai/papers/10.1182/blood-2010-12-327437
The paper
Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D. S., & Bhatia, R. (2011). Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. https://doi.org/10.1182/blood-2010-12-327437

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.